Our iLCT clinical trials
Our phase 3 International Linked Clinical Trials (iLCT)
Ambroxol
Ambroxol is already being used to treat respiratory conditions. Cure Parkinson’s has supported a phase 2 clinical trial to test efficacy in treating Parkinson’s, and is supporting a further phase 3 clinical trial, designed to test the long-term efficacy of ambroxol in slowing the progression of Parkinson’s.
Ambroxol and Parkinson’s
Exenatide
Exenatide (also known as Bydureon) is a clinically available and widely used drug for the treatment of Type 2 diabetes. Cure Parkinson’s is investigating the repurposing of exenatide to treat the progression of Parkinson’s. The recruitment for this trial is now complete.
Exenatide and Parkinson’sThe phase 2 International Linked Clinical Trials
The ‘PROSEEK Study’ – KO706 for Parkinson’s (recruiting now)
The drug named KO706 (a c-Abl inhibitor) is very similar to a drug called nilotinib (also a c-Abl inhibitor) which was supported into trial by Cure Parkinson’s. KO706 has been designed to better access the brain.
The Anle138b Phase 1b Study (recruitment complete)
Anle138b is a promising drug that targets the toxic accumulation of alpha-synuclein with the aim of alleviating neurodegenerative symptoms. This study is now recruiting people with Parkinson’s to participate.
The ‘AZA-PD Study’ – Azathioprine and Parkinson’s (recruitment complete)
This medication is already in use as a treatment for inflammation and the AZA-PD trial is looking at dampening down the immune response as a way of slowing the progression of Parkinson’s. The trial is being conducted in Cambridge (UK) and is supported by Cure Parkinson’s.
The ‘NLY-01’ Trial (recruitment complete)
A similar drug to exenatide, NLY-01 is designed to better access the brain. This drug was highly prioritised by the International Linked Clinical Trials (iLCT) committee in 2017. Similar drugs to NLY-01 already approved for the treatment of type 2 diabetes include exenatide, lixisenatide, and liraglutide – all three of these drugs have been or are being trialled in Parkinson’s through our iLCT programme. We are delighted to see Neuraly move NLY-01 into a phase 2 clinical trial in the U.S.
The ‘FAIR-PARK Study’ – Deferiprone and Parkinson’s (awaiting full results to be published)
Deferiprone is an iron chelator – a class of medication used to remove excess iron from the body. There is evidence that reducing iron in the brain can be beneficial for Parkinson’s.
Liraglutide and lixisenatide in Parkinson’s (awaiting full results to be published)
Like exenatide, liraglutide and lixisenatide are part of a group of drugs called GLP-1R agonists, used to treat type 2 diabetes. Cure Parkinson’s is supporting these trials to determine their impact on the progression of Parkinson’s.
The ‘UP-Study’ – UDCA and Parkinson’s (awaiting full results to be published)
UDCA is used in the treatment of gallstones and has been determined to have beneficial effects on mitochondrial function in pre-clinical models of Parkinson’s. The UP study – UDCA in Parkinson’s, supported by Cure Parkinson’s, has now completed and we are awaiting results.
The APM Trials – Australian Parkinson’s Mission
The Australian Parkinson’s Mission (APM) is a 5-year clinical trial project funded by the Australian Federal Government. The first trial is testing three drugs that have been prioritised by the International Linked Clinical Trials initiative, comparing them with a single placebo. Further APM trials are being set up.